Sandro De Falco Selected Research

Pathologic Neovascularization

4/2021	Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis.
1/2020	Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization.
2/2018	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.
1/2018	Targeting VEGF receptors with non-neutralizing cyclopeptides for imaging applications.
1/2018	Full Functional Knockout of Placental Growth Factor by Knockin with an Inactive Variant Able to Heterodimerize with VEGF-A.
7/2015	The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
4/2014	Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions.
1/2013	Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities.
12/2012	Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer.
6/2011	The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandro De Falco Research Topics

Disease

16	Neoplasms (Cancer) 12/2020 - 08/2002
13	Pathologic Neovascularization 04/2021 - 01/2004
7	Choroidal Neovascularization 04/2021 - 04/2009
7	Inflammation (Inflammations) 10/2019 - 03/2008
5	Ischemia 04/2021 - 08/2002
4	Neoplasm Metastasis (Metastasis) 05/2017 - 03/2008
3	Macular Degeneration (Age-Related Maculopathy) 01/2021 - 01/2016
3	Hypoxia (Hypoxemia) 05/2017 - 04/2014
3	Arthritis (Polyarthritis) 01/2010 - 01/2004
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 02/2018
2	Retinal Diseases 01/2021 - 02/2018
2	Blindness (Hysterical Blindness) 01/2020 - 12/2012
2	Parkinson Disease (Parkinson's Disease) 01/2020 - 08/2010
2	Macular Edema 10/2019 - 11/2017
2	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 04/2015
2	Rheumatoid Arthritis 03/2015 - 02/2009
2	Carcinoma (Carcinomatosis) 06/2011 - 01/2011
2	Experimental Arthritis 01/2010 - 02/2009
1	Pathologic Processes 01/2021
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2021
1	Retinal Vein Occlusion 02/2018
1	Vascular Diseases (Vascular Disease) 02/2018
1	Glioma (Gliomas) 05/2017
1	Corneal Neovascularization 01/2016
1	Fibrosarcoma 01/2016
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Ulcer 01/2015
1	T-Cell Leukemia (Leukemia, T Cell) 03/2014
1	Colonic Neoplasms (Colon Cancer) 01/2014
1	Teratocarcinoma 01/2013
1	Melanoma (Melanoma, Malignant) 06/2011
1	Intermittent Claudication 03/2010
1	Peripheral Arterial Disease 03/2010
1	Hyperplasia 01/2010
1	Breast Neoplasms (Breast Cancer) 08/2008
1	Body Weight (Weight, Body) 01/2004
1	Atherosclerosis 01/2004

Drug/Important Bio-Agent (IBA)

19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2002
9	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2018 - 01/2004
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 07/2015 - 03/2008
4	Retinaldehyde (Retinal)IBA 04/2021 - 02/2018
3	Peptides (Polypeptides)IBA 04/2015 - 01/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2021 - 02/2009
2	Vascular Endothelial Growth Factor BIBA 01/2021 - 07/2015
2	afliberceptIBA 10/2019 - 11/2017
2	Pharmaceutical PreparationsIBA 05/2018 - 01/2014
2	Bevacizumab (Avastin)FDA Link 04/2015 - 01/2014
2	Collagen Type II (Type II Collagen)IBA 01/2010 - 02/2009
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 04/2021
1	LigandsIBA 01/2021
1	AntibodiesIBA 12/2020
1	SynucleinsIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 10/2019
1	Prostaglandins FIBA 02/2018
1	Oxygen (Dioxygen)IBA 02/2018
1	Transcription Factors (Transcription Factor)IBA 05/2017
1	Proteins (Proteins, Gene)FDA Link 05/2017
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2016
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2015
1	Irinotecan (Camptosar)FDA LinkGeneric 04/2015
1	Monoclonal AntibodiesIBA 04/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2015
1	AntioxidantsIBA 01/2015
1	Histones (Histone)IBA 04/2014
1	ent-kaurane 15-ketoatractyligenin methyl esterIBA 03/2014
1	atractyligenineIBA 03/2014
1	ThioredoxinsIBA 03/2014
1	nutlin 3IBA 10/2013
1	entinostat (MS 275)IBA 01/2013
1	Therapeutic UsesIBA 01/2013
1	Histone Deacetylase InhibitorsIBA 01/2013
1	Angiogenesis InhibitorsIBA 07/2011
1	amentoflavoneIBA 06/2011
1	Carnitine (L-Carnitine)FDA LinkGeneric 03/2010
1	Neuropilin-1IBA 01/2010
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2010
1	AutoantibodiesIBA 01/2010
1	Toll-Like Receptor 3IBA 04/2009
1	Small Interfering RNA (siRNA)IBA 04/2009
1	Double-Stranded RNA (RNA, Double Stranded)IBA 04/2009
1	Interleukin-6 (Interleukin 6)IBA 02/2009
1	Placenta Growth FactorIBA 02/2009
1	CytokinesIBA 02/2009
1	ErbB Receptors (EGF Receptor)IBA 08/2008
1	vandetanib (ZD6474)IBA 08/2008
1	Phosphotransferases (Kinase)IBA 08/2008
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 05/2006
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2004
1	Citrate (si)-Synthase (Synthase, Citrate)IBA 01/2004

Therapy/Procedure

6	Lasers (Laser) 04/2021 - 12/2012
5	Therapeutics 01/2020 - 08/2010
1	Intravitreal Injections 04/2015
1	Subcutaneous Injections 01/2010
1	Sutures (Suture) 04/2009